The most widely used CAR-T system in B-cell malignancies is the CD19-targeted CAR T cells which are already approved for the treatment of pediatric B-ALL and diffuse large B-cell lymphoma after impressive results in clinical trials [83,84]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.